Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: Yahoo! Finance
Autolus Therapeutics logo Autolus Therapeutics (NASDAQ:AUTL) Chief Executive Officer Christian Itin told conference attendees the company is entering its second year as a commercial-stage business following the launch of its first product, obe-cel , a CD19 CAR-T therapy approved for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Itin said the company generated $75 million in revenue in the first year of launch and “achieved market leadership very quickly,” reaching that position by the second quarter after launching at the beginning of last year. Launch progress and 2026 revenue guidance In the U.S., Autolus is currently active in “approximately 70 centers ,” with plans to expand to “ 80+ centers ” during the course of this year. Itin emphasized that CAR-T delivery requires each treatment center to be qualified and added to a license, making expansion a process-driven effort. ? Defense Stocks Are Soaring—AeroVironment's Earnings Could
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Autolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™PR Newswire
- CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™PR Newswire
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
AUTL
Earnings
- 11/12/25 - Miss
AUTL
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form SCHEDULE
- 1/26/26 - Form 424B3
- AUTL's page on the SEC website